Market Tracker

04/26 4:54pm ET

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

70.07
Delayed Data
As of 4:00pm ET
 +3.92 / +5.93%
Today’s Change
51.05
Today|||52-Week Range
135.59
+19.94%
Year-to-Date
Intercept Reports Phase III Sub-Study Liver Biopsy Data
Apr 16 / Zacks.com - Paid Partner Content
Bristol-Myers Collaborates With Harvard Fibrosis Network
Apr 13 / Zacks.com - Paid Partner Content
Gilead (GILD) Presents Encouraging Data on NASH Therapies
Apr 16 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close66.15
Today’s open66.61
Day’s range65.99 - 70.26
Volume835,505
Average volume (3 months)877,231
Market cap$1.6B
Data as of 4:00pm ET, 04/26/2018

Growth & Valuation

Earnings growth (last year)+14.10%
Earnings growth (this year)+14.48%
Earnings growth (next 5 years)-6.36%
Revenue growth (last year)+424.85%
P/E ratioNM
Price/Sales11.18
Price/Book98.43

Competitors

 Today’s
change
Today’s
% change
MDCOMedicines Co+1.58+5.56%
AGIOAgios Pharmaceutical...+1.07+1.27%
SAGESAGE Therapeutics In...+3.30+2.35%
PBHPrestige Brands Hold...-0.13-0.41%
Data as of 4:02pm ET, 04/26/2018

Financials

Next reporting dateMay 16, 2018
EPS forecast (this quarter)-$3.46
Annual revenue (last year)$131.0M
Annual profit (last year)-$360.4M
Net profit margin-275.18%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Mark E. Pruzanski
Chief Operating Officer
Jerome B. Durso
Corporate headquarters
New York, New York

Forecasts